FDA Approves Fifth Neulasta Biosimilar
The FDA approved Fylnetra, a biosimilar to Neulasta, for treating febrile neutropenia in cancer patients undergoing chemotherapy. Developed by Amneal Pharmaceuticals and Kashiv Biosciences, it marks the fifth pegfilgrastim biosimilar approval in the US. Amneal plans to launch Fylnetra, Releuko, and Alymsys in 2022.
Reference News
FDA Approves Fifth Neulasta Biosimilar
The FDA approved Fylnetra, a biosimilar to Neulasta, for treating febrile neutropenia in cancer patients undergoing chemotherapy. Developed by Amneal Pharmaceuticals and Kashiv Biosciences, it marks the fifth pegfilgrastim biosimilar approval in the US. Amneal plans to launch Fylnetra, Releuko, and Alymsys in 2022.